Ropes & Gray and Dorsey & Whitney advised on Rosemont Pharmaceuticals’ acquisition of Aytu BioPharma.
Rosemont Pharmaceuticals, a portfolio company of mid-market private equity firm Inflexion, has agreed to acquire Aytu BioPharma (Nasdaq: AYTU), a US specialty pharmaceutical company focused on advancing medicines for complex central nervous system (CNS) diseases. The transaction was announced on November 16 and is expected to close in December 2026.
The acquisition adds an established attention-deficit/hyperactivity disorder (ADHD) portfolio and an emerging Major Depressive Disorder (MDD) asset alongside a US commercial platform to Rosemont’s product development, regulatory, manufacturing and commercial expertise. A wholly owned subsidiary of Rosemont will commence a tender offer to acquire all outstanding shares of Aytu common stock at US$2.70 per share in cash, representing a 41.1% premium to Aytu’s 30-day volume-weighted average share price. Following successful completion of the tender offer, Rosemont will acquire all remaining shares not tendered, other than shares for which appraisal rights are properly exercised, through a second-step merger at the same price paid in the tender offer.
Ropes & Gray represented Rosemont Pharmaceuticals in the transaction.
The team was led by Mergers & Acquisitions Partner Jackie Cohen and Associate Joseph DiCarlo, and Private Equity Partner Janet Coscino and Associate Mike Augustyn. The team also included IP Transactions Partner David McIntosh, Litigation & Enforcement Partner Lisa Bebchick and Counsel Alison McLaughlin, Health Care Partner Jamie Darch, Employment, Executive Compensation & Benefits Partner Renata Ferrari, and Tax Partner David Saltzman.
Dorsey & Whitney LLP is serving as legal counsel to Aytu BioPharma.